


JFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19242

In Re Application Of: **David Andrew Anderson, et al.**



Application No. 10/553,683	Filing Date October 18, 2006	Examiner Nicole Kinsey	Customer No. 23389	Group Art Unit 1648	Confirmation No. 1846
-------------------------------	---------------------------------	---------------------------	-----------------------	------------------------	--------------------------

Title:

**VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN
AND PROTEIN OF INTEREST**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19242

In Re Application of: David Andrew Anderson, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/553,683	October 18, 2006	Nicole Kinsey	23389	1648	1846

Title:

**VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN
AND PROTEIN OF INTEREST**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 29, 2007
(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Dated: May 29, 2007

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

cc:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David Andrew Anderson, et al. **Examiner:** Nicole Kinsey
Serial No.: 10/553,683 **Art Unit:** 1648
Filed: October 18, 2006 **Docket:** 19242
For: VIRAL VECTORS EXPRESSING **Dated:** May 29, 2007
FUSION OF VIRAL LARGE ENVELOPE
PROTEIN AND PROTEIN OF INTEREST

Confirmation No.: 1846

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. PCT International Publication No. WO 02/10416 A1, published February 7, 2002;
2. Netter H.J. et al., "Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes", *Journal of Virology* 75(5):2130-2141 (2001), XP-002977998;
3. Bisht H. et al., "Recombinant Dengue Virus Type 2 Envelope/Hepatitis B Surface Antigen Hybrid Protein Expressed in *Pichia Pastoris* Can Function as a Bivalent Immunogen", *Journal of Biotechnology* 99(2):97-110 (2002), XP-002425482;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 29, 2007


Xiaochun Zhu

4. Pumpens P. et al., "Evaluation of HBs, HBc, and frCP Virus-Like Particles for Expression of Human Papillomavirus 16 E7 Oncoprotein Epitopes", *Intervirology* 45:24-32 (2002), XP-008026494;
5. Firat H. et al., "Design of a Polyepitope Construct for the Induction of HLA-A0201-Restricted HIV 1-Specific CTL Responses Using *HLA-A *0201* Transgenic, *H-2* Class I KO Mice", *European Journal of Immunology* 31(10):3064-3074 (2001), XP-002252815; and
6. Hofmann C. et al., "Hepatocyte-Specific Binding of L/S-HBV Particles Expressed in Insect Cells", *Biological Chemistry* 376(3):173-178 (1995), XP-000910500.

The references were cited in a Supplementary International Search Report dated April 4, 2007 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Supplementary Search Report. The relevance of the above-identified references has been described in the Supplementary International Search Report.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,



Xiaochun Zhu


Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

XZ:dg

Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)



Atty. Docket No. (Optional)

20242

Application Number

10/553,683

Applicant(s)

David Andrew Anderson, et al.

Filing Date

October 18, 2006

Group Art Unit

1648

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 02/10416 A1	2/7/02	PCT			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Netter H.J. et al., "Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes", <i>Journal of Virology</i> 75(5):2130-2141 (2001), XP-002977998
		Bisht H. et al., "Recombinant Dengue Virus Type 2 Envelope/Hepatitis B Surface Antigen Hybrid Protein Expressed in <i>Pichia Pastoris</i> Can Function as a Bivalent Immunogen", <i>Journal of Biotechnology</i> 99(2):97-110 (2002), XP-002425482
		Pumpens P. et al., "Evaluation of HBs, HBc, and frCP Virus-Like Particles for Expression of Human Papillomavirus 16 E7 Oncoprotein Epitopes", <i>Intervirology</i> 45(1):24-32 (2002), XP-008026494
		Firat H. et al., "Design of a Polyepitope Construct for the Induction of HLA-A0201-Restricted HIV 1-Specific CTL Responses Using <i>HLA-A *0201</i> Transgenic, <i>H-2</i> Class I KO Mice", <i>European Journal of Immunology</i> 31(10):3064-3074 (2001), XP-002252815
		Hofmann C. et al., "Hepatocyte-Specific Binding of L/S-HBV Particles Expressed in Insect Cells", <i>Biological Chemistry</i> 376(3):173-178 (1995), XP-000910500

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.